VelosBio

About:

VelosBio is a next-generation oncology company, developing novel antibody-drug conjugates to treat haematological cancers.

Website: http://www.velosbio.com/

Top Investors: OrbiMed, Farallon Capital Management, Cormorant Asset Management, Wellington Management, Viking Global Investors

Description:

VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers. It was founded in 2017 and headquartered in San Diego, California.